Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Declines By 18.1%

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a significant drop in short interest in November. As of November 15th, there was short interest totalling 2,900,000 shares, a drop of 18.1% from the October 31st total of 3,540,000 shares. Approximately 6.0% of the company’s stock are short sold. Based on an average trading volume of 321,000 shares, the days-to-cover ratio is currently 9.0 days.

Wall Street Analysts Forecast Growth

ATXS has been the subject of several recent research reports. Oppenheimer boosted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Thursday, November 14th. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $25.60.

Hedge Funds Weigh In On Astria Therapeutics

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after acquiring an additional 480,184 shares during the period. Tidal Investments LLC purchased a new stake in shares of Astria Therapeutics during the 1st quarter worth approximately $1,664,000. Vestal Point Capital LP increased its position in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after buying an additional 750,000 shares in the last quarter. Sofinnova Investments Inc. purchased a new stake in shares of Astria Therapeutics in the second quarter valued at about $552,000. Finally, ClariVest Asset Management LLC purchased a new position in Astria Therapeutics during the second quarter worth $731,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Price Performance

Shares of ATXS stock traded up $0.11 during mid-day trading on Monday, hitting $10.50. The stock had a trading volume of 86,539 shares, compared to its average volume of 599,522. Astria Therapeutics has a 12-month low of $4.67 and a 12-month high of $16.90. The firm’s 50-day moving average is $11.10 and its two-hundred day moving average is $10.64. The firm has a market capitalization of $592.52 million, a P/E ratio of -4.97 and a beta of 0.71.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.